Agreed. Obviously the patent loss completely changed the future course for Amarin. And my assumption is that JT and his henchmen truly thought Vascepa could be a blockbuster, and weren't willing to part with it for a "modest" buyout (what would have been modest relative to their stock price at the time).
News 
Market Data 
Discover 
